A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease

Christopher H. van Dyck,Adam P. Mecca,Ryan S. O’Dell,Hugh H. Bartlett,Nina G. Diepenbrock,Yiyun Huang,Mary E. Hamby,Michael Grundman,Susan M. Catalano,Anthony O. Caggiano,Richard E. Carson
DOI: https://doi.org/10.1186/s13195-024-01382-2
2024-01-26
Alzheimer s Research & Therapy
Abstract:Effective, disease-modifying therapeutics for the treatment of Alzheimer's disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ oligomers are among the most toxic forms of Aβ. CT1812 is a novel brain penetrant sigma-2 receptor ligand that interferes with the binding of Aβ oligomers to neurons. Preclinical studies of CT1812 have demonstrated its ability to displace Aβ oligomers from neurons, restore synapses in cell cultures, and improve cognitive measures in mouse models of AD. CT1812 was found to be generally safe and well tolerated in a placebo-controlled phase 1 clinical trial in healthy volunteers and phase 1a/2 clinical trials in patients with mild to moderate dementia due to AD. The unique objective of this study was to incorporate synaptic positron emission tomography (PET) imaging as an outcome measure for CT1812 in AD patients.
neurosciences,clinical neurology
What problem does this paper attempt to address?